Basis: (FMP quote price / unrounded diluted TTM EPS) / five-year diluted EPS CAGR in percent, from annual statements through the period end shown. Source: stored company filings and market data; unavailable inputs remain N/A.
The PEG ratio is N/A as of 2026-10-06T17:04:09.371Z.
Calculation as of: 2026-10-06T17:04:09.371Z.
Quote observation: 2026-10-06T16:59:23.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 77ffd79d43f0055242b38282a97f53e69ef3ec7586b4a3f7de15a7f16befe37a
PEG RATIO
N/A
SpyGlass Pharma, Inc. Common Stock
Market Cap
$840.18M
PEG Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$832.41M
PEG Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PEG RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| SpyGlass Pharma, Inc. Common Stock (SGP) | $840.18M | N/A | N/A | N/A | N/A |
| Monte Rosa Therapeutics, Inc. (GLUE)vs › | $839.73M | N/A | N/A | N/A | N/A |
| Alumis Inc. (ALMS)vs › | $835.64M | N/A | N/A | N/A | N/A |
| Beta Bionics, Inc. (BBNX)vs › | $833.62M | N/A | N/A | N/A | N/A |
| Pacific Biosciences of California, Inc. (PACB)vs › | $832.41M | N/A | N/A | N/A | N/A |
| QuidelOrtho Corporation (QDEL)vs › | $858.87M | N/A | 0.68 | 0.68 | 0.68 |
| SI-BONE, Inc. (SIBN)vs › | $861.70M | N/A | N/A | N/A | N/A |
| SL Science Holding Ltd (SLBT)vs › | $863.01M | N/A | N/A | N/A | N/A |
| Rigel Pharmaceuticals, Inc. (RIGL)vs › | $865.07M | N/A | N/A | N/A | N/A |
| Jade Biosciences, Inc. (JBIO)vs › | $810.71M | N/A | N/A | N/A | N/A |
PEG Ratio
N/A
P/E Ratio
N/A
PEG Ratio = P/E Ratio / 5-Year Diluted EPS CAGR (%)
The PEG ratio divides the price-to-earnings ratio by the company's five-year compound annual growth rate of diluted EPS, expressed in percent. A P/E of 20 and a five-year diluted EPS CAGR of 10% give a PEG of 2.0. The growth is reported, historical earnings growth from annual statements, not an analyst forecast. A PEG near 1 is often read as fairly priced for its growth; lower can mean cheaper relative to growth. The ratio is N/A when the P/E is unavailable or not positive, or when the five-year diluted EPS CAGR is unavailable or not positive. Each day of the history uses the CAGR that was known on that day.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
